What Have We Learned from the Tau Hypothesis?

  • Ricardo B. Maccioni
  • Gustavo A. Farias
  • Leonel E. Rojo
  • M. Alejandra Sekler
  • Rodrigo O. Kuljis


Until the appearance of the Danger Signals Hypothesis on Alzheimer’s disease (AD), none of the hypotheses on its pathogenesis accounted coherently for the diversity of the earliest events that trigger neurodegeneration, and that eventually result in senile plaques (SP) and neurofibrillary tangles (NFTs). The original version of the most commonly held amyloid hypothesis rests on the concept that amyloid-β (Aβ)1–42 self-polymerizes over many years to form SP, which then triggers the entire array of subsequent brain lesions. However, recent findings point to unpleated Aβ oligomers (ADDLs) as the major culprit for synaptic impairment, well before neuronal degeneration ensues. Amyloid deposits thus appear to be a rather late event in a long chain driving progressively more severe neuronal, glial and neuropil alterations. AD is a multifactorial disorder in that protein alterations, oxidative stress, neuroinflammation, immune deregulation, impairment of neuronal-glial communication, and neurotoxic agents appear to be the major factors triggering neuronal degeneration, and the balance among these seems to vary from patient to patient. Although diverse, these factors induce deleterious signaling through different sets of neuronal receptors that converge in the hyperphosphorylation of tau molecules. Thus, tau hyperphosphorylation constitutes a common final pathway for most of the altered molecular and cellular factors that eventually result in degenerating neurons. This raises the question as to precisely what triggers the pathological phosphorylation. We have shown that Aβ oligomers, oxygen free radicals, and iron overload destabilize the equilibrium between the activities of protein phosphatases and kinases involved in tau assembly. Furthermore, overproduction or processing alterations of trophic factors such as NGF by activated glial cells trigger signaling cascades via p75, leading to cdk5 activation, followed by tau hyperphosphorylation and neuronal death. The cytokines TNFα, IL-1, and IL-6 induce activation of the cdk5/p35 complex, which causes tau phosphorylation.

Converging lines of evidence reveal the involvement of innate immunity (in contrast with the more widely acknowledged, but probably less-important involvement of adaptive immunity) and the role of inflammatory processes in the development of AD-associated neuronal changes. While methodological challenges cannot be ruled out in the interpretation of the so far confusing and sometimes even contradictory clinical trials, inflammation is essential in virtually all animal models for AD-like lesions. Taken together, these observations indicate that slowly accumulating danger/alarm signals to the innate immune system interfere with the balance of protective versus degeneration-promoting mechanisms, shifting the equilibrium toward neurodegeneration that involves deregulation of protein kinases cdk5 and GSKβ, tau hyperphosphorylation, and its aggregation into anomalous polymers in the neuronal cytoskeleton that constitutes the converging result of a large array of risk factors over time. These mediate the inexorable worsening of cognitive manifestations along with neuronal degeneration and the eventual appearance of tardy lesions such as SP and NFTs. This new theoretical framework based on recent experimental findings may serve as a powerful tool in the development of the much-sought biomarkers and in vivo imaging technology for the early diagnosis of AD. This will also help in the design of effective interventions to both treat and perhaps even prevent this increasingly prevalent brain disorder.


Neuronal Degeneration Senile Plaque Neuronal Cytoskeleton Straight Filament Neurodegenerative Cascade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.




Alzheimer's disease


Aβ oligomers neurotoxic for the synapses, β-structure, secondary structure type beta of a protein


cyclin-dependent protein kinase 5

C-terminal domain

carboxyl-terminal domain, GSK3β, glycogen synthase kinase β


cerebrospinal fluid

IL-1 and -6

interleukins 1 and 6


microtubule-associated proteins


neurofibrillary tangles


paired helical filaments


senile plaques


tumor necrosis factor-α.



Research was supported by grants from FONDECYT 1080254 and the International Center for Biomedicine (ICC) to RBM. We appreciate the sound contributions of Dr. Jorge Fernandez, Leonardo Navarrete, and Karen Neumann.


  1. 1.
    Alzheimer A (1907) A singular disorder that affects the cerebral cortex. In: Hochberg CN, Hochberg FH (eds) Neurologic Classics in Modern Translation. Hafner Press, New York: Hafner Press, 1977, pp. 41–43Google Scholar
  2. 2.
    Maccioni RB, Concha I, Otths C, Muñoz JP (2001) The protein kinase cdk5: structural aspects, roles in neurogenesis and involvement in Alzheimer's pathology. Eur J Biochem 268:1518–1529PubMedCrossRefGoogle Scholar
  3. 3.
    Maccioni RB, Barbeito L, Muñoz JP (2001) The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 32:367–381PubMedCrossRefGoogle Scholar
  4. 4.
    Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83:4913–4917PubMedCrossRefGoogle Scholar
  5. 5.
    Kosik KS, Joachim CL, Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83:4044–4048PubMedCrossRefGoogle Scholar
  6. 6.
    Maccioni RB, Cambiazo V (1995) Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 75:835–864PubMedGoogle Scholar
  7. 7.
    Maccioni RB, Rivas CI, Vera JC (1988) Differential interaction of synthetic peptides from the carboxyl-terminal regulatory domain of tubulin with microtubule-associated proteins. EMBO J 7:1957–1963PubMedGoogle Scholar
  8. 8.
    Maccioni RB, Vera JC, Dominguez J, Avila J (1989) A discrete repeated sequence defines a tubulin binding domain on microtubule-associated protein tau. Arch Biochem Biophys 275:568–579PubMedCrossRefGoogle Scholar
  9. 9.
    Moraga D, Rivas-Berrios A, Farias G, Wallin M, Maccioni RB (1992) Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau. Biochim Biophys Acta 1121:97–103PubMedCrossRefGoogle Scholar
  10. 10.
    Moraga DM, Nunez P, Garrido J, Maccioni RB (1993) A tau fragment containing a repetitive sequence induces bundling of actin filaments. J Neurochem 61:979–986PubMedCrossRefGoogle Scholar
  11. 11.
    Cross D, Muñoz JP, Hernández P, Maccioni RB (2000) Nuclear and cytoplasmic tau proteins from human non-neuronal cells share common structural/functional features with brain tau. J Cell Biochem 78:305–317PubMedCrossRefGoogle Scholar
  12. 12.
    González-Billault C, Farías G, Maccioni RB (1998) Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. Cell Mol Biol 44:1117–1127Google Scholar
  13. 13.
    Farias GA, Vial C, Maccioni RB (1993) Functional domains on chemically modified tau protein. Cell Mol Neurobiol 13:173–182PubMedCrossRefGoogle Scholar
  14. 14.
    Farias G, Gonzalez-Billault C, Maccioni RB (1997) Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau. Mol Cell Biochem 168:59–66PubMedCrossRefGoogle Scholar
  15. 15.
    Farias G, Muñoz JP, Garrido J, Maccioni RB (2002) Tubulin, actin and tau protein interactions and the study of their macromolecular assemblies. J Cell Biochem 85:315–324PubMedCrossRefGoogle Scholar
  16. 16.
    Alvarez A, Toro R, Cáceres A, Maccioni RB (1999) Inhibition of tau phosphorylating kinase cdk-5 by butyrolactone and tau antisense probes prevents amyloid-induced neuronal death. FEBS Lett 459:421–426PubMedCrossRefGoogle Scholar
  17. 17.
    Alvarez A, Muñoz JP, Maccioni RB (2001) A cdk5/p35 stable complex is involved in the beta-amyloid induced deregulation of cdk5 activity in hippocampal neurons. Exp Cell Res 264:266–275PubMedCrossRefGoogle Scholar
  18. 18.
    Tabaton M, Mandybur TI, Perry G, Onorato M, Autilio-Gambetti L, Gambetti P (1989) The widespread alteration of neurites in Alzheimer's disease may be unrelated to amyloid deposition. Ann Neurol 26:771–778PubMedCrossRefGoogle Scholar
  19. 19.
    Ghoshal N, García-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder LI (2002) Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 177:475–493PubMedCrossRefGoogle Scholar
  20. 20.
    Sjoberg MK, Shestakova E, Mansoroglu Z, Maccioni RB, Bonnefoy E (2006) Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J Cell Sci. 119(Pt 10):2025–2034PubMedCrossRefGoogle Scholar
  21. 21.
    Zhu X, Lee HG, Perry G, Smith MA (2007) Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta 1772:494–502PubMedGoogle Scholar
  22. 22.
    Rojo L, Fernandez J, Maccioni AA, Jimenez J, Maccioni RB (2008) Neuro-inflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res 39:1–16PubMedCrossRefGoogle Scholar
  23. 23.
    Fernandez J, Rojo LE, Kuljis RO, Maccioni RB (2008) The damage signal hypothesis of AD pathogenesis. J Alzheimers Dis 14:329–333Google Scholar
  24. 24.
    Glenner GG, Wong CW (1984) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131–1135PubMedCrossRefGoogle Scholar
  25. 25.
    Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRefGoogle Scholar
  26. 26.
    Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. Life 59:332–345PubMedGoogle Scholar
  27. 27.
    Lavados M, Farias G, Rothhammer F, Guillón M, Maccioni CB, Maccioni RB (2005) ApoE alleles and tau markers in patients with different levels of cognitive impairment. Arch Med Res 36:474–479PubMedCrossRefGoogle Scholar
  28. 28.
    Maccioni RB, Lavados M, Maccioni CB, Mendoza A (2004) Biological markers of Alzheimer's disease and mild cognitive impairment. Curr Alz Res 1:307–314CrossRefGoogle Scholar
  29. 29.
    Maccioni RB, Lavados M, Maccioni CB, Farias G, Fuentes P (2006) Anomalously phosphorylated tau protein and Abeta fragments in the CSF of Alzheimer's and MCI subjects. Neurobiol Aging 27:237–244PubMedCrossRefGoogle Scholar
  30. 30.
    Damasio AR (1994) Descartes Error: emotion, Reason and the Human Brain. Avon BooksGoogle Scholar
  31. 31.
    Rubia (2001) “El cerebro nos engaña?” Eds.: Ediciones temas de hoy, Madrid, pp. 339Google Scholar
  32. 32.
    Maccioni RB, Muñoz JP, Maccioni CB (2003) Dimensiones bioéticas de la investigación sobre el genoma humano (Bioethical dimensions of research on the human genome). Acta Bioética 10:75–81Google Scholar
  33. 33.
    Katzman R (1993) Education and the prevalence of dementia and Alzheimer's disease. Neurology 43:13–20PubMedGoogle Scholar
  34. 34.
    Khachaturian ZS (1998) An overview of Alzheimer's disease research. Am J Med 104(4A):26S–31SPubMedCrossRefGoogle Scholar
  35. 35.
    Terry RD (2000) Where in the brain does Alzheimer's disease begin? Ann Neurol 47:421PubMedCrossRefGoogle Scholar
  36. 36.
    Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 Census. Arch Neurol 60:1119–1122PubMedCrossRefGoogle Scholar
  37. 37.
    Delacourte A (2006) The natural and molecular history of Alzheimer's disease. J Alzheimers Dis 9(3 Suppl):187–194PubMedGoogle Scholar
  38. 38.
    Andreadis A (2005) Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. Biochim Biophys Acta 1739:91–103PubMedGoogle Scholar
  39. 39.
    Kuljis RO (1994) Lesions in the pulvinar in patients with AD. J Neuropathol Exp Neurol 53:202–211PubMedCrossRefGoogle Scholar
  40. 40.
    Kuljis RO, Tikoo RK (1997) Discontinuous distribution of senile plaques in striate hypercolumns in Alzheimer's disease. Vision Res 37:3537–3591CrossRefGoogle Scholar
  41. 41.
    Duff K, Planel E (2005) Untangling memory deficit. Nat Med 11:826–827PubMedCrossRefGoogle Scholar
  42. 42.
    Berger Z, Roder H, Hanna A (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27:3650–3662PubMedCrossRefGoogle Scholar
  43. 43.
    Drewes G, Lichtenberg-Kraag B, Doring F (1992) Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 11:2131PubMedGoogle Scholar
  44. 44.
    Wille H, Drewes G, Biernat J, Mandelkow EM, Mandelkow E (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118:573–584PubMedCrossRefGoogle Scholar
  45. 45.
    .Perez M, Arrasate M, Montejo E, de Garcini. Munoz V, Avila J (2001) In vitro assembly of tau protein: mapping the regions involved in filament formation. Biochemistry 40:5983–5991Google Scholar
  46. 46.
    Rivas CI, Vera JC, Maccioni RB (1988) Anti-idiotypic antibodies that react with microtubule-associated proteins are present in the sera of rabbits immunized with synthetic peptides from tubulin's regulatory domain. Proc Natl Acad Sci USA 85:6092–6096PubMedCrossRefGoogle Scholar
  47. 47.
    Vera JC, Rivas CI, Maccioni RB (1988) Antibodies to synthetic peptides from the tubulin regulatory domain interact with tubulin and microtubules. Proc Natl Acad Sci USA 85:6763–6767PubMedCrossRefGoogle Scholar
  48. 48.
    Cann JR, York EJ, Stewart JM, Vera JC, Maccioni RB (1988) Small zone gel chromatography of interacting systems: theoretical and experimental evaluation of elution profiles for kinetically controlled macromolecule-ligand reactions. Anal Biochem 175:462–473PubMedCrossRefGoogle Scholar
  49. 49.
    Cross D, Vial C, Maccioni RB (1993) A tau like protein interacts with stress fibers and microtubules in human and rodent cultured cell lines. J Cell Sci 105:51–60PubMedGoogle Scholar
  50. 50.
    Henriquez JP, Cross D, Vial C, Maccioni RB (1995) Subpopulations of tau interact with microtubules and actin filaments in various cell types. Cell Biochem Funct 13:239–250PubMedCrossRefGoogle Scholar
  51. 51.
    Cross D, Tapia L, Garrido J, Maccioni RB (1996) Tau-like proteins associated with centrosomes in cultured cells. Exp Cell Res 229:378–387PubMedCrossRefGoogle Scholar
  52. 52.
    Sibille N, Sillen A, Leroy A (2006) Structural impact of heparin binding to full-length tau as studied by NMR spectroscopy. Biochemistry 45:12560–12572PubMedCrossRefGoogle Scholar
  53. 53.
    Appelt DM, Balin BJ (1993) Analysis of paired helical filaments (PHFs) found in Alzheimer's disease using freeze-drying/rotary shadowing. J Struct Biol 111:85–95PubMedCrossRefGoogle Scholar
  54. 54.
    von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E (2000) Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci USA 97:5129–5134PubMedCrossRefGoogle Scholar
  55. 55.
    Mukrasch MD, Markwick P, Biernat J (2007) Highly populated turn conformations in natively unfolded tau protein identified from residual dipolar couplings and molecular simulation. J Am Chem Soc 129:5235–5243PubMedCrossRefGoogle Scholar
  56. 56.
    Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A (2006) Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res 54:197–201PubMedCrossRefGoogle Scholar
  57. 57.
    Rojo L, Avila M, Chandía M, Becerra R, Maccioni RB (2007) 18F Lanzoprazole: chemical and biological studies towards the development of new PET radiopharmaceuticals, International Conference on Clinical PET and Molecular Nuclear Medicine, 10–14 November 2007, Bangkok, ThailandGoogle Scholar
  58. 58.
    Rojo L, Sjoberg M, Hernandez P, Zambrano C, Maccioni RB (2006) Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J Biomed Biotech 2006:1–17CrossRefGoogle Scholar
  59. 59.
    Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:245–257PubMedCrossRefGoogle Scholar
  60. 60.
    Mendoza-Naranjo A, Gonzalez-Billault C, Maccioni RB (2007) Abeta1–42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. J Cell Sci 120(Pt 2):279–288PubMedCrossRefGoogle Scholar
  61. 61.
    Perry G, Castellani RJ, Hirai K, Smith M (1998) Reactive oxygen species mediate cellular damage in Alzheimer's disease. J Alzheimers Dis 1:45–55PubMedGoogle Scholar
  62. 62.
    Zambrano CA, Egana JT, Nunez MT, Maccioni RB, Gonzalez-Billault C (2004) Oxidative stress promotes tau dephosphorylation in neuronal cells: the roles of cdk5 and PP1. Free Radic Biol Med 36:1393–1402PubMedCrossRefGoogle Scholar
  63. 63.
    Lavados M, Guillon M, Mujica MC, Rojo L, Fuentes P, Maccioni RB (2008) Mild cognitive impairment and Alzheimer's patients display different levels of redox-active CSF iron. J Alzheimers Dis 13:225–232PubMedGoogle Scholar
  64. 64.
    Orellana D, Quntanilla RA, Gonzalez C, Maccioni RB (2005) Role of JAKs/STAT pathway in the intracellular calcium changes induced by interleukin-6 in hippocampal neurons. Neurotoxicity Res 8:295–304CrossRefGoogle Scholar
  65. 65.
    Orellana DI, Quintanilla RA, Maccioni RB (2007) Neuroprotective effect of TNFalpha against the beta-amyloid neurotoxicity mediated by cdk5 kinase. Biochim Biophys Acta 1773:254–263PubMedCrossRefGoogle Scholar
  66. 66.
    Saez M, Pehar M, Barbeito L, Maccioni RB (2004) Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18:275–280PubMedGoogle Scholar
  67. 67.
    Saez M, Pehar M, Vargas M, Barbeito L, Maccioni RB (2006) Production of NGF by β-amyloid stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hypocampal cells. J Neurosci Res 84:1098–1106PubMedCrossRefGoogle Scholar
  68. 68.
    Muñoz JP, Alvarez A, Maccioni RB (2000) Regulation of the expression of the cyclin-dependent protein kinase cdk5 during laminin-induced neuritic development in neuroblastoma cells. Neuroreport 11:12–21CrossRefGoogle Scholar
  69. 69.
    Tarkowski E, Blennow K, Wallin A, Tarkowski A (1999) Intracerebral production of TNF-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19:223–230PubMedCrossRefGoogle Scholar
  70. 70.
    Otth C, Concha II, Arendt T (2002) AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4:417–430PubMedGoogle Scholar
  71. 71.
    Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates cdk5 activity and promotes neurodegeneration. Nature 402:615–622PubMedCrossRefGoogle Scholar
  72. 72.
    Fischer HC, Kuljis RO (1994) Multiple type of nitrogen monoxide synthase/NAPH diaphorase containing neurons in the human cerebral neocortex. Brain Res 654:105–107PubMedCrossRefGoogle Scholar
  73. 73.
    Hernanz A, De la Fuente M, Navarro M, Frank A (2007) Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Neuroimmunomodulation 14:163–167PubMedCrossRefGoogle Scholar
  74. 74.
    Kuljis RO, Shapshak P, Alcabes P, Rodríguez de la Vega P, Fujimura R, Petito CK (2002) Increased density of neurons containing NADPH diaphorase and nitric oxide synthase in the cerebral cortex of patients with HIV-1 infection and drug abuse. J NeuroAIDS 2:19–36PubMedGoogle Scholar
  75. 75.
    Kuljis RO (1997) Modular corticocerebral pathology in Alzheimer's disease. In: Mangone CA, Allegri RF, Arizaga RL, Ollari JA (eds) Dementia: a Multidisciplinary Approach. Editorial Sagitario, Buenos Aires, Argentina, pp. 143–155.Google Scholar
  76. 76.
    Kuljis RO, Schelper RL (1996) Alterations in nitrogen monoxide-synthesizing cortical neurons in amyotrophic lateral sclerosis with dementia. J Neuropathol Exp Neurol 55:25–35PubMedCrossRefGoogle Scholar
  77. 77.
    Kuljis RO (2008) Alzheimer’s disease (updated entry). eMedicine (available online at
  78. 78.
    Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C (2002) Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 23:485–508PubMedCrossRefGoogle Scholar
  79. 79.
    Klunk WE, Engler H, Nordberg A, (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306–319PubMedCrossRefGoogle Scholar
  80. 80.
    Santa-Maria I, Perez M, Hernandez F, Avila J, Moreno FJ (2006) Characteristics of the binding of thioflavin S to tau paired helical filaments. J Alzheimers Dis 9:279–285PubMedGoogle Scholar
  81. 81.
    von Bergen M, Berghorns S, Biernat J, Mandelkow EM, Madelkow E (2005) Tau aggregation is driven from a transition coil to beta sheet structure. Biochem Biophys Acta 3:1739Google Scholar
  82. 82.
    Okamura N, Suemoto T, Furumoto S (2005) Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25:10857–10862PubMedCrossRefGoogle Scholar
  83. 83.
    Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62:196–200PubMedCrossRefGoogle Scholar
  84. 84.
    Verhoeff NP, Wilson AA, Takeshita S, (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C] SB-13 PET. Am J Geriatr Psychiatry 12:584–595PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Ricardo B. Maccioni
    • 1
  • Gustavo A. Farias
    • 1
  • Leonel E. Rojo
    • 1
  • M. Alejandra Sekler
    • 1
  • Rodrigo O. Kuljis
    • 1
  1. 1.Department of PsychiatryFaculty of Medicine, U ChileProvidenciaChile

Personalised recommendations